Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Sarah Zohar"'
Autor:
Mårten Vågerö, Martin Posch, Frank Miller, Siew Wan Hee, Jason Madan, Michael Pearce, Simon Day, Nigel Stallard, Sarah Zohar
Publikováno v:
Pharmaceutical Statistics. 17:214-230
We discuss 3 alternative approaches to sample size calculation: traditional sample size calculation based on power to show a statistically significant effect, sample size calculation based on assurance, and sample size based on a decision-theoretic a
Publikováno v:
Revue d'Épidémiologie et de Santé Publique. 69:S14
Introduction Master protocol designs (basket, umbrella, platform) allow simultaneous comparison of multiple treatments or disease subgroups. Master protocols can be also designed as seamless studies, in which two or more clinical phases are considere
The Simon's two-stage design is the most commonly applied among multi-stage designs in phase IIA clinical trials. It combines the sample sizes at the two stages in order to minimize either the expected or the maximum sample size. When the uncertainty
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a89ebc7e04a624f590f0fa99b2251d59
http://hdl.handle.net/11577/3283095
http://hdl.handle.net/11577/3283095
Autor:
Jason Madan, Siew Wan Hee, Frank Miller, Simon Day, Martin Posch, Nigel Stallard, Sarah Zohar
Publikováno v:
Biometrical Journal. 59:609-625
The problem of choosing a sample size for a clinical trial is a very common one. In some settings, such as rare diseases or other small populations, the large sample sizes usually associated with the standard frequentist approach may be infeasible, s
Autor:
Martin Posch, Frank Miller, Nigel Stallard, Sarah Zohar, Jason Madan, Simon Day, Michael Pearce, Siew Wan Hee
Publikováno v:
BMC Medical Research Methodology
BMC Medical Research Methodology, BioMed Central, 2018, 18 (1), pp.20. ⟨10.1186/s12874-018-0475-0⟩
BMC Medical Research Methodology, Vol 18, Iss 1, Pp 1-9 (2018)
BMC Medical Research Methodology, 2018, 18 (1), pp.20. ⟨10.1186/s12874-018-0475-0⟩
BMC Medical Research Methodology, BioMed Central, 2018, 18 (1), pp.20. ⟨10.1186/s12874-018-0475-0⟩
BMC Medical Research Methodology, Vol 18, Iss 1, Pp 1-9 (2018)
BMC Medical Research Methodology, 2018, 18 (1), pp.20. ⟨10.1186/s12874-018-0475-0⟩
Background Most confirmatory randomised controlled clinical trials (RCTs) are designed with specified power, usually 80% or 90%, for a hypothesis test conducted at a given significance level, usually 2.5% for a one-sided test. Approval of the experim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36145dfd74d83387ac0ce595dcfc5367
http://wrap.warwick.ac.uk/99080/1/WRAP-value-iinformation-methods-design-Stallard-2018.pdf
http://wrap.warwick.ac.uk/99080/1/WRAP-value-iinformation-methods-design-Stallard-2018.pdf
Publikováno v:
Archives of disease in childhood. 103(11)
To review characteristics, methodology and reporting of non-inferiority and equivalence trials in the specific context of paediatrics.PubMed and Cochrane databases were searched (up to September 2016) for non-inferiority/equivalence randomised contro
Autor:
Jason Madan, Catrin Tudur Smith, Martin Posch, Nigel Stallard, Sarah Zohar, Siew Wan Hee, Frank Miller, Simon Day, Adrian Willis
Publikováno v:
Orphanet Journal of Rare Diseases
Orphanet Journal of Rare Diseases, 2016, 12 (1), pp.44. ⟨10.1186/s13023-017-0597-1⟩
Orphanet Journal of Rare Diseases, BioMed Central, 2016, 12 (1), pp.44. ⟨10.1186/s13023-017-0597-1⟩
Orphanet Journal of Rare Diseases, 2016, 12 (1), pp.44. 〈10.1186/s13023-017-0597-1〉
ORPHANET JOURNAL OF RARE DISEASES
Orphanet Journal of Rare Diseases, 2016, 12 (1), pp.44. ⟨10.1186/s13023-017-0597-1⟩
Orphanet Journal of Rare Diseases, BioMed Central, 2016, 12 (1), pp.44. ⟨10.1186/s13023-017-0597-1⟩
Orphanet Journal of Rare Diseases, 2016, 12 (1), pp.44. 〈10.1186/s13023-017-0597-1〉
ORPHANET JOURNAL OF RARE DISEASES
Background: Clinical trials are typically designed using the classical frequentist framework to constrain type I and II error rates. Sample sizes required in such designs typically range from hundreds to thousands of patients which can be challenging
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c0392319081c0ca6734bd0e738af1f0
https://www.hal.inserm.fr/inserm-01481651/document
https://www.hal.inserm.fr/inserm-01481651/document
Autor:
John F. Gerecitano, Alexia Iasonos, John O'Quigley, David R. Spriggs, Sarah Zohar, David M. Hyman, Mrinal M. Gounder
Publikováno v:
Clinical Cancer Research. 18:5179-5187
The rate of observed dose-limiting toxicities (DLT) determines the maximum tolerated dose (MTD) in phase I trials. There are cases in which non–drug-related toxicities or other-cause toxicities (OCT) are flagged as DLTs, or vice versa, due to attri
Publikováno v:
Statistics in Medicine. 31:4243-4254
The aim of an exploratory clinical trial is to determine whether a new intervention is promising for further testing in confirmatory clinical trials. Most exploratory clinical trials are designed as single-arm trials using a binary outcome with or wi
Publikováno v:
Revue d'Épidémiologie et de Santé Publique. 65:S59-S60
Introduction A pervasive problem when comparing treatments based on randomized clinical trials in children, rare diseases, or important disease subgroups, is that the sample size often is too small to obtain a confirmatory conclusion using convention